GlassScriptPhysician profile
John F Best
NPI 1154373462
$1,505.03
in general payments reported to CMS, 2019-2025
16 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $137 · 2021: $330 · 2022: $103 · 2023: $264 · 2024: $256 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638 · Education: $18.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.03 |
| Education | $18.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $455.72 | 2019-2025 | Watchman Flx, Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Astrazeneca Pharmaceuticals LP | $137.19 | 2023-2025 | Fasenra, Breztri |
| Abiomed | $133.61 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.81 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.00 | 2022-2024 | Ofev, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $92.03 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $91.42 | 2019-2021 | |
| Amgen INC. | $84.85 | 2021-2024 | Repatha, Tavneos |
| Merck Sharp & Dohme LLC | $79.68 | 2021-2022 | |
| Pfizer INC. | $74.88 | 2019-2023 | |
| Philips North America LLC | $29.23 | 2023 | |
| Jazz Pharmaceuticals INC. | $28.62 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $27.30 | 2022-2023 | Uptravi, Opsumit |
| Grifols USA, LLC | $24.54 | 2023 | Prolastin-C Liquid |
| E.R. Squibb & Sons, L.L.C. | $18.18 | 2023 | Camzyos |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $14.97 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Best listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.